Drug Master File for Glioblastoma Therapy Product Filed with FDA
Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to the FDA for TLX101 (4-[131I]Iodol-phenylalanine injection)
Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Drug Master File (DMF) to the United States Food and Drug Administration (FDA DMF No. 034931) for TLX101 (4-[131I]Iodol-phenylalanine injection).
TLX101 is a clinical-stage drug candidate targeting Large Neutral Amino Acid Transporter (LAT-1) for the treatment of glioblastoma multiforme (GBM).
To read media release please click here.